Baotou Dongbao Bio-Tech Co Ltd (300239) - Net Assets
Based on the latest financial reports, Baotou Dongbao Bio-Tech Co Ltd (300239) has net assets worth CN¥1.69 Billion CNY (≈ $247.61 Million USD) as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥2.54 Billion ≈ $372.24 Million USD) and total liabilities (CN¥851.75 Million ≈ $124.64 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check financial resilience of Baotou Dongbao Bio-Tech Co Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.69 Billion |
| % of Total Assets | 66.52% |
| Annual Growth Rate | 19.7% |
| 5-Year Change | 74.26% |
| 10-Year Change | 146.19% |
| Growth Volatility | 41.36 |
Baotou Dongbao Bio-Tech Co Ltd - Net Assets Trend (2008–2024)
This chart illustrates how Baotou Dongbao Bio-Tech Co Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is Baotou Dongbao Bio-Tech Co Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for Baotou Dongbao Bio-Tech Co Ltd (2008–2024)
The table below shows the annual net assets of Baotou Dongbao Bio-Tech Co Ltd from 2008 to 2024. For live valuation and market cap data, see how much is Baotou Dongbao Bio-Tech Co Ltd worth.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥1.74 Billion ≈ $254.53 Million |
-8.12% |
| 2023-12-31 | CN¥1.89 Billion ≈ $277.03 Million |
+7.82% |
| 2022-12-31 | CN¥1.76 Billion ≈ $256.94 Million |
+9.49% |
| 2021-12-31 | CN¥1.60 Billion ≈ $234.67 Million |
+60.66% |
| 2020-12-31 | CN¥998.18 Million ≈ $146.07 Million |
+0.64% |
| 2019-12-31 | CN¥991.86 Million ≈ $145.14 Million |
+32.09% |
| 2018-12-31 | CN¥750.88 Million ≈ $109.88 Million |
+2.89% |
| 2017-12-31 | CN¥729.75 Million ≈ $106.79 Million |
+1.52% |
| 2016-12-31 | CN¥718.86 Million ≈ $105.19 Million |
+1.74% |
| 2015-12-31 | CN¥706.55 Million ≈ $103.39 Million |
+107.47% |
| 2014-12-31 | CN¥340.56 Million ≈ $49.83 Million |
-3.11% |
| 2013-12-31 | CN¥351.47 Million ≈ $51.43 Million |
+8.47% |
| 2012-12-31 | CN¥324.03 Million ≈ $47.42 Million |
+9.47% |
| 2011-12-31 | CN¥295.99 Million ≈ $43.31 Million |
+141.74% |
| 2010-12-31 | CN¥122.44 Million ≈ $17.92 Million |
+21.64% |
| 2009-12-31 | CN¥100.65 Million ≈ $14.73 Million |
+2.85% |
| 2008-12-31 | CN¥97.87 Million ≈ $14.32 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Baotou Dongbao Bio-Tech Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1640.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥411.41 Million | 23.65% |
| Common Stock | CN¥593.61 Million | 34.12% |
| Other Components | CN¥734.52 Million | 42.23% |
| Total Equity | CN¥1.74 Billion | 100.00% |
Baotou Dongbao Bio-Tech Co Ltd Competitors by Market Cap
The table below lists competitors of Baotou Dongbao Bio-Tech Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
XiAn Typical Industries Co Ltd
SHG:600302
|
$483.03 Million |
|
S.C. CHIMCOMPLEX S.A.
RO:CRC
|
$483.08 Million |
|
Shenzhen Huakong Seg Co Ltd
SHE:000068
|
$483.17 Million |
|
Shandong Meichen Science & Technology Co Ltd
SHE:300237
|
$483.18 Million |
|
CHTC Helon Co Ltd
SHE:000677
|
$482.95 Million |
|
Skandinaviska Enskilda Banken AB (publ)
ST:SEB-C
|
$482.93 Million |
|
Zhejiang Aokang Shoes Co Ltd
SHG:603001
|
$482.90 Million |
|
Capital Bancorp
NASDAQ:CBNK
|
$482.74 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Baotou Dongbao Bio-Tech Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,658,061,663 to 1,739,542,623, a change of 81,480,960 (4.9%).
- Net income of 85,982,726 contributed positively to equity growth.
- Dividend payments of 15,808,830 reduced retained earnings.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥85.98 Million | +4.94% |
| Dividends Paid | CN¥15.81 Million | -0.91% |
| Other Changes | CN¥11.31 Million | +0.65% |
| Total Change | CN¥- | 4.91% |
Book Value vs Market Value Analysis
This analysis compares Baotou Dongbao Bio-Tech Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.07x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 16.84x to 2.07x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2008-12-31 | CN¥0.33 | CN¥5.56 | x |
| 2009-12-31 | CN¥0.34 | CN¥5.56 | x |
| 2010-12-31 | CN¥0.41 | CN¥5.56 | x |
| 2011-12-31 | CN¥0.86 | CN¥5.56 | x |
| 2012-12-31 | CN¥0.82 | CN¥5.56 | x |
| 2013-12-31 | CN¥0.89 | CN¥5.56 | x |
| 2014-12-31 | CN¥0.86 | CN¥5.56 | x |
| 2015-12-31 | CN¥1.74 | CN¥5.56 | x |
| 2016-12-31 | CN¥1.56 | CN¥5.56 | x |
| 2017-12-31 | CN¥1.58 | CN¥5.56 | x |
| 2018-12-31 | CN¥1.63 | CN¥5.56 | x |
| 2019-12-31 | CN¥1.96 | CN¥5.56 | x |
| 2020-12-31 | CN¥1.90 | CN¥5.56 | x |
| 2021-12-31 | CN¥2.52 | CN¥5.56 | x |
| 2022-12-31 | CN¥2.57 | CN¥5.56 | x |
| 2023-12-31 | CN¥2.71 | CN¥5.56 | x |
| 2024-12-31 | CN¥2.69 | CN¥5.56 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Baotou Dongbao Bio-Tech Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 4.94%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 9.72%
- • Asset Turnover: 0.34x
- • Equity Multiplier: 1.51x
- Recent ROE (4.94%) is below the historical average (6.61%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2008 | 12.15% | 9.98% | 0.60x | 2.04x | CN¥2.11 Million |
| 2009 | 11.29% | 7.33% | 0.75x | 2.06x | CN¥1.30 Million |
| 2010 | 17.66% | 11.24% | 0.87x | 1.80x | CN¥9.38 Million |
| 2011 | 8.34% | 11.89% | 0.55x | 1.28x | CN¥-4.93 Million |
| 2012 | 10.92% | 13.84% | 0.53x | 1.50x | CN¥2.98 Million |
| 2013 | 12.13% | 11.16% | 0.74x | 1.48x | CN¥7.49 Million |
| 2014 | 1.44% | 1.95% | 0.47x | 1.56x | CN¥-29.17 Million |
| 2015 | 0.83% | 2.02% | 0.37x | 1.10x | CN¥-64.77 Million |
| 2016 | 2.67% | 6.07% | 0.38x | 1.16x | CN¥-52.66 Million |
| 2017 | 3.07% | 6.29% | 0.37x | 1.33x | CN¥-50.56 Million |
| 2018 | 4.52% | 7.50% | 0.38x | 1.60x | CN¥-41.11 Million |
| 2019 | 3.59% | 7.24% | 0.37x | 1.33x | CN¥-63.58 Million |
| 2020 | 1.86% | 4.11% | 0.32x | 1.43x | CN¥-80.55 Million |
| 2021 | 2.56% | 5.96% | 0.29x | 1.48x | CN¥-105.79 Million |
| 2022 | 7.16% | 11.60% | 0.41x | 1.51x | CN¥-43.41 Million |
| 2023 | 7.23% | 12.30% | 0.36x | 1.65x | CN¥-45.92 Million |
| 2024 | 4.94% | 9.72% | 0.34x | 1.51x | CN¥-87.97 Million |
Industry Comparison
This section compares Baotou Dongbao Bio-Tech Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $1,347,197,696
- Average return on equity (ROE) among peers: 4.46%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Baotou Dongbao Bio-Tech Co Ltd (300239) | CN¥1.69 Billion | 12.15% | 0.50x | $482.96 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $2.84 Billion | -41.97% | 9.13x | $1.22 Billion |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $638.89 Million | 0.88% | 0.70x | $438.59 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $1.05 Billion | 10.46% | 0.19x | $5.18 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $1.07 Billion | 3.83% | 0.46x | $2.81 Billion |
| Wedge Industrial Co Ltd (000534) | $1.29 Billion | 11.69% | 1.47x | $2.95 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $35.11 Million | 18.13% | 0.80x | $13.85 Billion |
| Hainan Haiyao Co Ltd (000566) | $5.08 Billion | 1.71% | 1.08x | $949.23 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $141.91 Million | 11.01% | 0.32x | $391.07 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $994.58 Million | 2.01% | 2.11x | $1.03 Billion |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $332.48 Million | 26.89% | 0.68x | $3.30 Billion |
About Baotou Dongbao Bio-Tech Co Ltd
Baotou Dongbao Bio-Tech Co.,Ltd engages in the design, research and development, production, and sale of gelatin and collagen and their derivative products in the People's Republic of China and internationally. It offers pharmaceutical gelation, food additives gelatin, and photographic gelatin; hydrolyzed collagen, collagen peptide, fish collagen peptide, and agglomerated collagen; and private la… Read more